EZH2 overexpression in head and neck cancer is related to lymph node metastasis
Standard
EZH2 overexpression in head and neck cancer is related to lymph node metastasis. / Nienstedt, Julie C; Schroeder, Cornelia; Clauditz, Till; Simon, Ronald; Sauter, Guido; Muenscher, Adrian; Blessmann, Marco; Hanken, Henning; Pflug, Christina.
In: J ORAL PATHOL MED, Vol. 47, No. 3, 03.2018, p. 240-245.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EZH2 overexpression in head and neck cancer is related to lymph node metastasis
AU - Nienstedt, Julie C
AU - Schroeder, Cornelia
AU - Clauditz, Till
AU - Simon, Ronald
AU - Sauter, Guido
AU - Muenscher, Adrian
AU - Blessmann, Marco
AU - Hanken, Henning
AU - Pflug, Christina
N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2018/3
Y1 - 2018/3
N2 - BACKGROUND: Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2, plays an important role in tumor development and progression by interacting with histone and non-histone proteins. EZH2 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types.MATERIAL AND METHODS: This study investigates the prognostic relevance of immunohistochemical EZH2 expression in head and neck squamous cell carcinoma. Tissue microarray sections with 667 cancers of oral cavity, oro- and hypopharynx and larynx were analyzed for EZH2 expression.RESULTS: Nuclear EZH2 staining was recorded in 322 (81.8%) of 394 cases. Staining was weak in 33 (10.2%), moderate in 128 (39.6%), and strong in 103 (32.0%) cancers. The prevalence of EZH2 expression in tumors of the oral cavity and the orohypopharynx was higher as compared to cancers of the larynx (P = .0023). EZH2 expression was correlated to presence of lymph node metastasis (P = .0089) but was unrelated to histological grade, tumor stage, surgical margin, or distant metastasis. EZH2 expression had no impact on patient survival.CONCLUSION: The high prevalence of EZH2 expression in head and neck squamous cell carcinoma stresses its capability as a therapeutic target.
AB - BACKGROUND: Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2, plays an important role in tumor development and progression by interacting with histone and non-histone proteins. EZH2 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types.MATERIAL AND METHODS: This study investigates the prognostic relevance of immunohistochemical EZH2 expression in head and neck squamous cell carcinoma. Tissue microarray sections with 667 cancers of oral cavity, oro- and hypopharynx and larynx were analyzed for EZH2 expression.RESULTS: Nuclear EZH2 staining was recorded in 322 (81.8%) of 394 cases. Staining was weak in 33 (10.2%), moderate in 128 (39.6%), and strong in 103 (32.0%) cancers. The prevalence of EZH2 expression in tumors of the oral cavity and the orohypopharynx was higher as compared to cancers of the larynx (P = .0023). EZH2 expression was correlated to presence of lymph node metastasis (P = .0089) but was unrelated to histological grade, tumor stage, surgical margin, or distant metastasis. EZH2 expression had no impact on patient survival.CONCLUSION: The high prevalence of EZH2 expression in head and neck squamous cell carcinoma stresses its capability as a therapeutic target.
KW - Journal Article
U2 - 10.1111/jop.12673
DO - 10.1111/jop.12673
M3 - SCORING: Journal article
C2 - 29285811
VL - 47
SP - 240
EP - 245
JO - J ORAL PATHOL MED
JF - J ORAL PATHOL MED
SN - 0904-2512
IS - 3
ER -
